Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA.

Science. 2009 Jul 17;325(5938):336-9. doi: 10.1126/science.1173110.

2.

Gain of RNA function in pathological cases: Focus on myotonic dystrophy.

Klein AF, Gasnier E, Furling D.

Biochimie. 2011 Nov;93(11):2006-12. doi: 10.1016/j.biochi.2011.06.028. Epub 2011 Jul 13. Review.

PMID:
21763392
3.

Pathogenic mechanisms of myotonic dystrophy.

Lee JE, Cooper TA.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1281-6. doi: 10.1042/BST0371281. Review.

4.

Tackling the pathogenesis of RNA nuclear retention in myotonic dystrophy.

Mastroyiannopoulos NP, Shammas C, Phylactou LA.

Biol Cell. 2010 Jul 23;102(9):515-23. doi: 10.1042/BC20100040. Review.

PMID:
20690904
5.
6.

Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.

Chau A, Kalsotra A.

Dev Dyn. 2015 Mar;244(3):377-90. doi: 10.1002/dvdy.24240. Epub 2015 Jan 13. Review.

7.

Myotonic dystrophy: RNA-mediated muscle disease.

Wheeler TM, Thornton CA.

Curr Opin Neurol. 2007 Oct;20(5):572-6. Review.

PMID:
17885447
8.

Myotonic dystrophy: discussion of molecular basis.

Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG.

Adv Exp Med Biol. 2002;516:27-45. Review. No abstract available.

PMID:
12611434
9.

RNA-dominant diseases.

Osborne RJ, Thornton CA.

Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R162-9. Review.

PMID:
16987879
10.

RNA-mediated neurodegeneration in repeat expansion disorders.

Todd PK, Paulson HL.

Ann Neurol. 2010 Mar;67(3):291-300. doi: 10.1002/ana.21948. Review.

11.

Myotonic dystrophy mouse models: towards rational therapy development.

Gomes-Pereira M, Cooper TA, Gourdon G.

Trends Mol Med. 2011 Sep;17(9):506-17. doi: 10.1016/j.molmed.2011.05.004. Epub 2011 Jul 2. Review.

12.

RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Echeverria GV, Cooper TA.

Brain Res. 2012 Jun 26;1462:100-11. doi: 10.1016/j.brainres.2012.02.030. Epub 2012 Feb 22. Review.

13.

[Myotonic Dystrophy: Advances in Translational Research].

Nakamori M, Takahashi MP.

Brain Nerve. 2017 Jan;69(1):61-69. doi: 10.11477/mf.1416200637. Review. Japanese.

PMID:
28126979
14.

MBNL proteins and their target RNAs, interaction and splicing regulation.

Konieczny P, Stepniak-Konieczna E, Sobczak K.

Nucleic Acids Res. 2014;42(17):10873-87. doi: 10.1093/nar/gku767. Epub 2014 Sep 2. Review.

15.

RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Kole R, Krainer AR, Altman S.

Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40. doi: 10.1038/nrd3625. Review.

16.

[Myotonic dystrophy].

Ishiura S, Oana K, Koebis M.

Rinsho Shinkeigaku. 2013;53(11):1109-11. Review. Japanese.

PMID:
24291894
17.

Impaired pre-mRNA processing and altered architecture of 3' untranslated regions contribute to the development of human disorders.

Michalova E, Vojtesek B, Hrstka R.

Int J Mol Sci. 2013 Jul 26;14(8):15681-94. doi: 10.3390/ijms140815681. Review.

18.

RNA toxicity and foci formation in microsatellite expansion diseases.

Zhang N, Ashizawa T.

Curr Opin Genet Dev. 2017 Jun;44:17-29. doi: 10.1016/j.gde.2017.01.005. Epub 2017 Feb 14. Review.

PMID:
28208060
19.

RNA imaging in living cells - methods and applications.

Urbanek MO, Galka-Marciniak P, Olejniczak M, Krzyzosiak WJ.

RNA Biol. 2014;11(8):1083-95. doi: 10.4161/rna.35506. Review.

Supplemental Content

Support Center